Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Development of Subvisible Particulate Matter Test – V 2.0

Posted on By

Analytical Method Development: SOP for Development of Subvisible Particulate Matter Test – V 2.0

Standard Operating Procedure for Development of Subvisible Particulate Matter Test in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/278/2025
Supersedes SOP/AMD/278/2022
Page No. Page 1 of 11
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To define a validated and regulatory-compliant procedure for the development and qualification of methods used for the detection and quantification of subvisible particulate matter

in injectable pharmaceutical products using light obscuration and microscopic techniques.

2. Scope

This SOP is applicable to Analytical Method Development and Quality Control departments involved in the establishment and validation of subvisible particulate matter testing for aqueous and non-aqueous parenteral drug products.

3. Responsibilities

  • Analytical Scientist: Develops and validates the method for subvisible particulate matter testing.
  • QC Analyst: Performs routine testing of injectable batches using approved methods.
  • QA Executive: Ensures test compliance with pharmacopoeial standards and reviews reports.
See also  Analytical Method Development: SOP for TGA Method for Moisture and Volatile Content - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that the developed method meets USP <788>, Ph. Eur. 2.9.19, and other applicable regulatory standards.

5. Procedure

5.1 Instrument Selection

  1. Use Light Obscuration Particle Counter as the primary method for aqueous injectables.
  2. Use Microscopic Particle Count method as alternate or confirmatory method for oil-based or viscous injectables.

5.2 Sample Preparation

  1. Collect test samples in clean glass containers under aseptic and particulate-free conditions.
  2. Degas and equilibrate samples to room temperature (20–25°C).
  3. Filter air and clean equipment before operation to minimize false readings.

5.3 Test Procedure (Light Obscuration)

  1. Perform calibration and verification of the instrument using certified polystyrene bead standards.
  2. Rinse sensor with WFI before and after each run.
  3. Inject at least three 5 mL aliquots of test solution; discard the first and average the next two.
  4. Record cumulative counts of ≥10 µm and ≥25 µm particles per mL.

5.4 Test Procedure (Microscopic Count)

  1. Filter 25 mL of sample through 0.8 µm membrane filter.
  2. Rinse filter with WFI and mount on microscope slide.
  3. Scan 10 fields under 100x magnification and record count of ≥10 µm and ≥25 µm particles.
See also  Analytical Method Development: SOP for Microbial Load Method Development for Creams - V 2.0

5.5 Acceptance Criteria (USP <788>)

  • For small volume injections (<100 mL):
    • NMT 6000 particles ≥10 µm per container
    • NMT 600 particles ≥25 µm per container
  • For large volume injections (≥100 mL):
    • NMT 25 particles/mL ≥10 µm
    • NMT 3 particles/mL ≥25 µm

5.6 Method Validation

  1. Precision: RSD ≤ 10% for replicate counts.
  2. Accuracy: Recovery of certified standards within ±10%.
  3. Specificity: Method should detect particles and distinguish from bubbles or dust.
  4. Linearity: Demonstrated by diluting a known particle suspension.
  5. Ruggedness: Perform testing with different analysts and instruments.

6. Abbreviations

  • RSD: Relative Standard Deviation
  • WFI: Water for Injection
  • USP: United States Pharmacopeia
  • Ph. Eur.: European Pharmacopoeia
  • QA: Quality Assurance

7. Documents

  1. Particulate Matter Test Log – Annexure-1
  2. Calibration Certificate for Particle Counter – Annexure-2
  3. Method Validation Report – Annexure-3

8. References

  • USP <788>: Particulate Matter in Injections
  • Ph. Eur. 2.9.19: Particulate Contamination
  • ICH Q2(R1): Validation of Analytical Procedures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Rakesh Pawar Vaishali Gupta Sunita Reddy
Designation Particle Testing Chemist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Particulate Matter Test Log

Sample ID ≥10 µm (particles/mL) ≥25 µm (particles/mL) Status
PMT-278-01 12 1 Pass

Annexure-2: Calibration Certificate

Calibration performed on 15/05/2025 using 10 µm and 25 µm NIST-traceable bead standards. Instrument performance was within limits.

Annexure-3: Method Validation Report

The developed method for subvisible particulate matter quantification was validated as per USP and ICH guidelines. Results demonstrated accuracy, precision, and ruggedness. Method deemed suitable for QC and stability testing.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Integrated microscopic method and updated validation strategy Annual Review Sunita Reddy
10/04/2022 1.0 Initial SOP Release New SOP QA Head
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Remote Monitoring of SOP Adherence: New Norms
Next Post: Inconsistent SOP Integration Across Sites: A Risk to Multi-Site GMP Compliance

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version